Describe Leishmaniasis - its vector, epidemiology
Leishmania is a genus containing over 20 species that are pathogenic for humans.
Vector –> It is transmitted by the small biting sandfly – two species of which transmit Leishmania: Phlebotomus in the eastern hemisphere (Africa, Europe and Asia) and Lutzomyia in western hemisphere (South and Central America).
Responsible for Leishmaniasis –> endemic in tropical regions throughout the world and is an emerging disease as number of reported cases are increasing.
Describe Leishmania’s life cycle
– During a blood meal, metacyclic promastigotes (present in the anterior portion of the gut and pharynx of the sandfly) are transferred to the blood of human.
In human
In the sandfly
What are the strategies Leishmania has developed to evade the immune response
– Leishmania attracts complement molecules so that it is engulfed by macrophages however it is not killed since it can resist the acidic pH –> it can ‘hide’ in macrophages.
– C3b binds to Leishmania in order to opsonize it but instead the parasite will express the gp63 protease that will convert it into iC3b which makes it more attractive to macrophages.
– It manipulates macrophages to release cytokines that will induce production of helper T cells which don’t have an effect on the parasite and inhibit CTL production.
– Leishmania is also protected from digestion in the phagolysome by its coat of LPG (lipophosphoglycan) which also affects macrophages microbial activity.
What are the different manifestations of Leishmaniasis?
Cutaneous Leishmaniasis
Mucosal cutaneous Leishmaniasis
Diffuse cutaneous Leishmaniasis
Visceral Leishmaniasis
What are the methods of treatment for Leishmaniasis
– A limited number of drugs are available, with most having toxicity and requiring long duration of therapy. Usually cutaneous form doesn’t require treatment.
– Most common treatment is pentavelent antimonials which are first line of treatment and are generally effective. However they have severe side effects - damaged veins, pancreatitis, hepatitis, myalgias, fatigue and cardiac problems. There’s emerging drug resistance.
– An alternative is liposomal amphotericin B – effective against visceral Leishmaniasis but also with severe side effects. Drug of last resort due to being expensive.
– An oral drug miltefosine has been approved for use in India – effective against VL, less toxic than other two and will be cheaper since hospitalization won’t be required. However effectiveness is species and location dependent.
How can parasite travel against the flow of blood in the sandfly in order to be transmitted to human?
The problem – parasites develop in the midgut and must exit through the food channel in the proboscis against the flow of blood.
What are the strategies the parasite has evolved to ensure transmission and to evade the immune response?
Transmission
Immunosuppressive
– Some components of vector’s saliva is expelled into bite wound and will have immunosuppressive actions against lymphocytes to increase infectivity of parasite.
– E.g. the peptide Maxadilan (MAX) – involved in inducing vasodilation and immunmodulation:-
• inhibits T-cell activation,
• stimulates the production of cytokines that favor a type 2 T-cell response - not effective against parasite.
• inhibits the production of molecules that de-activate macrophages (e.g. TNF-a and NO) since macrophages are necessary for their infection.
–> Vaccination against Maxadilan has shown to inhibit Leishmania infection.